Business Context and Reporting Period
Company: Apyx Medical Corp
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2026
Reporting Period: Event-based report for May 11, 2026
Apyx Medical Corporation, a Delaware corporation, filed this report to disclose a significant regulatory milestone regarding its product portfolio.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material change reported is a regulatory expansion for the company's flagship product:
- Regulatory Approval: Received expanded 510(k) clearance from the U.S. Food and Drug Administration (FDA).
- Product: AYON Body Contouring System™.
- Expansion Details: The clearance now includes power liposuction capabilities, broadening the system's clinical applications.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA clearance but does not include forward-looking guidance, financial outlook, or specific management commentary within the text of the 8-K itself.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in this filing beyond the standard disclosure of the regulatory event.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the commercial impact of the power liposuction clearance.
- Confirm the timeline for the commercial availability of the updated AYON Body Contouring System™.
- Review subsequent quarterly filings (10-Q) to assess the financial impact of this regulatory expansion on revenue and margins.
- Check for any additional regulatory requirements or post-market surveillance obligations associated with the expanded clearance.